Collegium Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Extends Collegium’s Long-Term Revenue Outlook; AZSTARYS...
1 Healthcare Stock with Competitive Advantages and 2 We Brush Off
COLL Q1 Deep Dive: ADHD Portfolio Expansion and Pain Segment Stability Drive Results
Collegium Pharmaceutical (NASDAQ:COLL) reported first-quarter 2026 results highlighting continued growth in its ADHD franchise led by JORNAY PM, steady performance from its pain portfolio, and progress...
Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q1 CY2026 Expectations, Stock Soars
Collegium Pharmaceutical: Q1 Earnings Snapshot
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year – – Generated JORNAY PM ® Quarterly Net Revenue of $38.9 Million, Up 36% Year-over-Year – – On Track...
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For